Non-alcoholic fatty liver disease and the metabolic syndrome: an update.
Sedentary lifestyle and poor dietary choices are leading to a weight gain epidemic in westernized countries, subsequently increasing the risk for developing the metabolic syndrome and nonalcoholic fatty liver disease (NAFLD). NAFLD is estimated to affect approximate 30% of the general US population and is considered the hepatic manifestation of the metabolic syndrome. Recent findings linking the components of the metabolic syndrome with NAFLD and the progression to nonalcoholic steatohepatitis (NASH) will be reviewed; in particular, the role of visceral adipose tissue, insulin resistance, and adipocytokines in the exacerbation of these conditions. While no therapy has been proven effective for treating NAFLD/NASH, common recommendations will be discussed.
Rector
R Scott
RS
Division of Gastroenterology and Hepatology, University of Missouri-Columbia, Columbia, MO 65212, United States.
Thyfault
John P
JP
Wei
Yongzhong
Y
Ibdah
Jamal A
JA
D015415:Biomarkers / Q000378:metabolism; D005234:Fatty Liver / Q000453:epidemiology* / Q000378:metabolism*; D006801:Humans; D024821:Metabolic Syndrome / Q000453:epidemiology* / Q000378:metabolism*; D015995:Prevalence
D015415:Biomarkers